Some patients report improved mood and reduced food-related anxiety, while others experience initial jitteriness or emotional blunting during dose escalation
GLP-1RAs represent a promising new strategy for patients with psychiatric disorders, offering the possibility of meaningful weight loss while also improving metabolic health changes that can significantly enhance quality of life. They undertook a systematic review and meta-analysis of ultimately nine RCTs to assess the efficacy and safety of GLP-1 RAs in individuals with psychiatric disorders (specifically, schizophrenia or schizoaffective disorder, bipolar disorder, psychosis, major depressive disorder, binge-eating disorder, or a combination) and obesity/overweight, focusing on weight and metabolic outcomes
Sergey Terushkin, MD, FACS Last Updated: April 30, 2026 If your weight loss has slowed or stopped on semaglutide, youre not aloneplateaus are a normal biological response
Conclusion GLP-1 receptor agonists like Mounjaro and Wegovy have revolutionised weight loss and diabetes care, offering significant benefits in both weight reduction and metabolic health